Inspire Medical Systems (INSP) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Inspire Medical Systems (NYSE: INSP) in the last few weeks:

• 8/4/2026 – Inspire Medical Systems had its “sector weight” rating reaffirmed by KeyCorp.
• 8/4/2026 – Inspire Medical Systems was given a new $54.00 price target by Evercore Inc.
• 8/4/2026 – Inspire Medical Systems had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $62.00 price target on the stock, up from $54.00.
• 8/4/2026 – Inspire Medical Systems had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $60.00 price target on the stock.
• 8/4/2026 – Inspire Medical Systems was given a new $75.00 price target by Stifel Nicolaus.
• 8/4/2026 – Inspire Medical Systems had its price target raised by Piper Sandler from $55.00 to $60.00. They now have a “neutral” rating on the stock.
• 8/4/2026 – Inspire Medical Systems had its price target raised by JPMorgan Chase & Co. from $54.00 to $60.00. They now have a “neutral” rating on the stock.
• 8/4/2026 – Inspire Medical Systems had its price target raised by Mizuho from $55.00 to $65.00. They now have an “outperform” rating on the stock.
• 8/4/2026 – Inspire Medical Systems had its price target raised by Robert W. Baird from $54.00 to $59.00. They now have a “neutral” rating on the stock.
• 8/4/2026 – Inspire Medical Systems was upgraded by Oppenheimer Holdings, Inc. from “market perform” to “outperform”. They now have a $85.00 price target on the stock.
• 8/3/2026 – Inspire Medical Systems had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 7/28/2026 – Inspire Medical Systems is now covered by UBS Group AG. They set a “sell” rating and a $39.00 price target on the stock.
• 7/28/2026 – Inspire Medical Systems is now covered by UBS Group AG. They set a “sell” rating and a $39.00 price target on the stock.
• 7/28/2026 – Inspire Medical Systems is now covered by UBS Group AG. They set a “sell” rating and a $39.00 price target on the stock.
• 7/16/2026 – Inspire Medical Systems had its price target raised by Truist Financial Corporation from $50.00 to $54.00. They now have a “hold” rating on the stock.
• 7/6/2026 – Inspire Medical Systems was upgraded by Zacks Research from “strong sell” to “hold”.
• 6/30/2026 – Inspire Medical Systems was upgraded by Freedom Capital to “strong-buy”.
• 6/23/2026 – Inspire Medical Systems was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $40.00 price target on the stock.
• 6/15/2026 – Inspire Medical Systems had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 6/15/2026 – Inspire Medical Systems was downgraded by Royal Bank Of Canada from “sector perform” to “buy”.

Insider Activity at Inspire Medical Systems

In related news, insider Jason P. Kelly sold 963 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the sale, the insider owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.20% of the stock is owned by company insiders.

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.